Clinical trials: Human Immunodeficiency Virus (HIV)
Chronic Kidney Failure, AIDS-Associated Nephropathy
Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients
Among adults with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS), Chronic Kidney Disease (CKD) has previously been reported to occur in approximately 10% of children with HIV-infection.
- Conditions
- Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
- Trial name
- NCT00153621
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- Children's National Research Institute
HIV Infections
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose…
- Trial name
- NCT06652958
- Testing
- VH4527079
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Positive, Malnourished
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
Children living with HIV from sub-Saharan Africa often present with severe malnutrition. In severe malnutrition, metabolic and/or gut structural derangement may lead to inadequate antiretroviral (ARV) absorption and/or erratic…
- Trial name
- NCT01818258
- Testing
- ZDV+3TC+LPV/r
- Where
- 5 sites in Malawi, Tanzania and 2 more
- Volunteers
- 52 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
AIDS Vaccines, HIV Infections
Phase 1 Safety Study of Two Experimental HIV Vaccines
This study will test whether two experimental HIV vaccines are safe and whether they cause any side effects in healthy adults. It will examine the body s immune response to the vaccines and monitor the social impact, if any, of…
- Conditions
- AIDS Vaccines, HIV Infections, HIV-1
- Trial name
- NCT00479999
- Testing
- VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Outcomes of Anti-HIV Therapy During Early HIV Infection
The purpose of this study is to find out if it is effective to give aggressive anti-HIV therapy to patients who have been infected recently with HIV.
- Trial name
- NCT00001093
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Activating Treatment as Prevention Through Community Mobilization in South Africa
The purpose of this study is to evaluate the impact of a community mobilization intervention on the uptake of HIV testing, linkage to and retention in HIV care using a community, cluster randomized trial.
- Trial name
- NCT02197793
- Testing
- Community Mobilization Program
- Where
- South Africa
- Volunteers
- 2,338 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV-1-infection, COVID-19
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV CoCo is a European multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for People Living With HIV (PLWHIV) who are co-infected…
- Trial name
- HIV CoCo (NCT05481216)
- Testing
- COVID-19, HIV-1 infection
- Where
- 23 sites in Belgium, France and 3 more
- Volunteers
- 2,598 people
- Sponsor
- NEAT ID Foundation
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
To extend the evaluation of safety and immunogenicity of MN recombinant soluble gp120/HIV-1 (MN rsgp120/HIV-1) in combination with QS21 with or without alum and on two different vaccination schedules.
- Trial name
- NCT00001052
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 5 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sexually Transmitted Infections
62% & 15% Ethanol in Emollient Gel as Topical Male Microbicides
The purpose of this study is to look at the safety and acceptance of using a microbicide (product that kills germs) gel to clean the genital area. Microbicide gel is used by hospital workers to clean their hands to kill germs.
- Trial name
- NCT00469547
- Testing
- 62% ethanol in emollient gel, 15% ethanol in emollient gel
- Where
- Kenya
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Washington
Human Immunodeficiency Virus
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative…
- Trial name
- NCT03110549
- Testing
- TMB-607
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth
Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.
- Conditions
- Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth, Pregnancy; Infection, Microbial Colonization
- Trial name
- NCT06131749
- Testing
- No intervention
- Where
- South Africa
- Volunteers
- 603 people
- Sponsor
- University of Bern
Infections, Human Immunodeficiency Virus and Herpesviridae
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor currently in Phase 3 clinical trials for the treatment of human immunodeficiency virus (HIV) infection.
- Trial name
- NCT01382238
- Testing
- Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Prevention
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
This is an open-label, steady-state study of Tenofovir (TFV) and Emtricitabine (FTC) pharmacokinetics (PK) in transgender women taking feminizing hormones.
- Trial name
- NCT03060785
- Testing
- Tenofovir Disoproxil Fumarate/Emtricitabine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions.
- Trial name
- NCT04276935
- Testing
- Interview, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infections
Anti-HIV Medications for People Recently Infected With HIV
It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in…
- Trial name
- NCT00106171
- Testing
- Highly active antiretroviral therapy (HAART)
- Where
- 5 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Human Immunodeficiency Virus
Rapid HIV Treatment Initiation, Access and Engagement in Care
The investigators propose to evaluate Rapid HIV Treatment Initiation in Baltimore in newly and previously diagnosed HIV-positive patients not in care through identification of barriers, facilitators and acceptability of Rapid HIV…
- Trial name
- NCT03512964
- Testing
- Dolutegravir 50 MG, Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Johns Hopkins University
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV (Human Immunodeficiency Virus), Alcohol Misuse
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
Randomized controlled trial to test the preliminary efficacy and mediating mechanism of a personalized normative feedback intervention on behavioral intentions, heavy alcohol use, and HIV/STI prevention among adolescents and…
- Conditions
- HIV (Human Immunodeficiency Virus), Alcohol Misuse, STI
- Trial name
- NCT07731932
- Testing
- PNF - HIV norms, PNF - Alcohol use norms, PNF - HIV and alcohol use norms
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
HIV
POC HIV Testing and Early DTG Use for Infants
This study is being conducted to explore the feasibility of implementing targeted birth HIV testing of high-risk neonates using facility-based point-of-care (POC) HIV diagnostics, and to improve the ability to implement the best…
- Trial name
- NCT05393193
- Testing
- Point-of-Care Cepheid Xpert HIV-1, DTG/ABC/3TC
- Where
- Botswana
- Volunteers
- 900 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV Infections
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.
- Trial name
- NCT05204121
- Testing
- Elpida
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Viriom